SequelSEC

Tonix Pharmaceuticals Holding Corp. TNXP

Pharmaceutical Preparations · CIK 0001430306 · Fiscal year ends 1231

Revenue
$29.10M
Fiscal year ended 2026-06-30
Operating income
-$165.42M
Fiscal year ended 2026-06-30
Free cash flow
-$158.11M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$271.37MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$20.24Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue20.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue25.7%87th
Gross margin49.3%27th
FCF margin-787.5%27th
Current ratio7.42x71th
Revenue YoY growth29.8%69th
Net margin-946.2%32th
Operating margin-959.1%34th
SBC / revenue45.9%61th
R&D / revenue339.4%59th

Tonix Pharmaceuticals Holding Corp. (TNXP) reported revenue of $29.10M and net income of -$159.67M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Tonix Pharmaceuticals Holding Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Tonix Pharmaceuticals Holding Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$29.10M
Cost of revenue$4.71M
Gross profit$24.40M
Operating income-$165.42M
Net income-$159.67M
Research & development$63.86M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$125.96M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Tonix Pharmaceuticals Holding Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$176.23M
Total assets$254.09M
Current assets$203.43M
Total liabilities$31.81M
Current liabilities$30.78M
Total equity incl. NCI$222.28M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$11.80M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$9.05M

Cash flow

Tonix Pharmaceuticals Holding Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$152.99M
Capital expenditures$5.12M
Investing cash flow-$4.26M
Financing cash flow$207.71M
Net change in cash$50.38M
Stock-based compensation$7.94M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.04M

Derived

Tonix Pharmaceuticals Holding Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$158.11M
Gross margin83.8%
Operating margin-568.4%
FCF margin-543.3%
SBC / revenue27.3%
Current ratio6.61x
Revenue YoY growth196.0%
Net margin-548.6%
R&D / revenue219.4%
CapEx / revenue17.6%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TNXP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.